SS-31 Improves Heart Mitochondria and Mitophagy in Barth Syndrome Mouse Model

Barth syndrome is a rare, X-linked genetic disorder primarily affecting males, characterized by cardiolipin deficiency leading to severe cardiomyopathy (heart muscle disease), skeletal myopathy, and neutropenia. This condition is often associated with significant mitochondrial dysfunction, including abnormal mitochondrial morphology and impaired mitophagy (the cellular process of clearing damaged mitochondria). Current treatments primarily manage symptoms, but there is a critical need for therapies that directly address the underlying mitochondrial pathology and improve cardiac function in these patients.

The study revealed that SS-31 treatment significantly improved cardiac mitochondrial health in the Barth syndrome model. Treated mice showed a 45% improvement in mitochondrial length and a 30% reduction in fragmented mitochondria compared to controls. The most striking finding was the 2.5-fold increase in functional mitophagy markers (e.g., LC3-II/LC3-I ratio) and a 60% decrease in the accumulation of dysfunctional mitochondria in the heart tissue of SS-31 treated animals. Furthermore, SS-31 restored key mitochondrial enzyme activities by an average of 35% and reduced oxidative stress markers by p<0.01, indicating a broad protective effect. These improvements were associated with a 20% enhancement in overall cardiac contractility, suggesting functional benefits.